New Obesity Guidelines: BMI No Longer the Only Metric, Waist Circumference and Muscle Mass Become Key

Central News Agency, Taipei, May 31. Taiwan's obesity treatment guidelines have recently undergone a major revision, introducing four key messages, including lowering the threshold for drug intervention, officially incorporating GLP-1 agonists (commonly known as 'skinny shots') and endoscopic weight loss procedures into treatment, and directly pointing out that BMI is no longer the only consideration for obesity, with waist circumference and muscle mass becoming key indicators. According to the latest statistics from the Health Promotion Administration of the Ministry of Health and Welfare, the overweight and obesity rate among adults in Taiwan has climbed to 50.3%, meaning one in every two adults faces the crisis of being overweight. Facing increasingly severe health challenges, the Taiwan Society for the Study of Obesity has officially released the latest version of the 'Taiwan Clinical Evidence-Based Guidelines for Adult Obesity.' Lin Wen-yuan, president of the Taiwan Society for the Study of Obesity, pointed out in a recent press release that the new guidelines emphasize that one should no longer look only at Body Mass Index (BMI). Although BMI is a widely used and convenient screening tool in public health, it cannot fully reflect an individual's health risks. What really needs attention is the proportion and distribution of body fat, especially visceral fat, which is most harmful to health. Lin said the new guidelines declare the end of the era of relying solely on BMI to monitor weight, shifting to a 'data-driven' core evaluation model. Clinical diagnosis no longer looks only at the number on the scale, but incorporates waist circumference, body fat percentage, muscle mass, and related comorbidities into an overall judgment. Among them, the waist circumference standard is 90 cm or more for men and 80 cm or more for women. Lin further pointed out that this shift helps identify the 'hidden obese' group, commonly known as 'puff people,' who have normal BMI but excessive visceral fat. Through more complete body composition analysis, medical teams can further evaluate the fat-to-muscle ratio and provide more precise treatment recommendations. The new guidelines list BMI 27 combined with comorbidities as an important threshold for medical intervention. Lin reminded that one should be vigilant if the BMI is 24 or higher and start health management early. Being overweight is often a pre-obesity stage. If one can adjust diet, exercise regularly, and improve lifestyle early, there is a chance to avoid continuous weight gain and reduce the risk of diabetes, stroke, cardiovascular disease, and dialysis. As GLP-1 receptor agonists, commonly known as 'skinny shots,' have attracted much attention, the new guidelines officially incorporate drugs into the regular treatment path. Chou Chu-kuang, director of the Weight Loss Center at Chiayi Christian Hospital, said that the new guidelines optimize the timing of drug initiation. While starting lifestyle management, it is evaluated to combine GLP-1 drug treatment early to accelerate the improvement of metabolic indicators and reduce long-term cardiovascular risks. In addition to 'skinny shots' being officially included in the treatment guidelines, Endoscopic Sleeve Gastroplasty (ESG) has also become a recommended treatment framework. Chou explained that ESG uses an endoscope to suture the stomach wall, using the reduction of stomach capacity to reshape satiety feedback signals. Studies show that patients can lose about 13.6% of their total body weight in 52 weeks, with a long-term stable weight loss rate of 15%. It is not suitable for all groups and requires a complete evaluation by a professional team.